Company profile
GlaxoSmithKline
Diversified pharma
Share price · GSK
$51.15+0.89 (+1.77%) 3M
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(51 total)
51Total Assets
27Approved
12Phase 3 / Filed
12Phase 1–2 / Early
16Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | Glucocorticoid receptor · Beta-2 adrenergic receptor · Glucocorticoid receptor / Beta-2 adrenergic receptorCombination | Asthma | |
| Approved | BCMAAntibody–drug conjugate | Multiple Myeloma | |
| Approved | BAFF / BLyS (B-lymphocyte stimulator) · BAFF (BLyS)Monoclonal antibody | Systemic Lupus Erythematosus | |
Daprodustat(Jesduvroq) | Approved | HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule | Chronic Kidney Disease |
| Approved | IL-5Monoclonal antibody | Chronic Obstructive Pulmonary DiseaseAsthma | |
Epoprostenol(Flolan) | Approved | IP receptor (prostacyclin pathway)Peptide | Hypertension |
Ezogabine(Potiga) | Approved | Kv7 potassium channelSmall molecule | Epilepsy |
| Approved | Glucocorticoid receptorSmall molecule | Asthma | |
| Approved | Glucocorticoid receptor + Muscarinic M3 receptor (ICS/LAMA combination) | Asthma | |
fluticasone furoate/umeclidinium/vilanterol(Trelegy Ellipta) | Approved | Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptor · Glucocorticoid receptor · Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3Small molecule | Chronic Obstructive Pulmonary DiseaseAsthma |
| Approved | Beta-2 adrenergic receptor · Glucocorticoid receptor · Glucocorticoid receptor / Beta-2 adrenergic receptorSmall molecule | Asthma | |
| Approved | M3 muscarinic acetylcholine receptor | Asthma | |
| Approved | Beta-2 adrenergic receptorSmall molecule | Asthma | |
| Approved | Beta-2 adrenergic receptor | Asthma | |
| Approved | Beta-2 adrenergic receptor | Asthma |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Research
Sign in to access ResearchUnlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Research
Sign in to access ResearchUnlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.